Last reviewed · How we verify
Ocrevus-US
Ocrevus-US is a monoclonal antibody that targets CD20 on B cells.
Ocrevus-US is a monoclonal antibody that targets CD20 on B cells. Used for Relapsing multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | Ocrevus-US |
|---|---|
| Also known as | Ocrelizumab |
| Sponsor | Sandoz |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Ocrevus-US works by binding to CD20, leading to the depletion of B cells, which are involved in the pathogenesis of multiple sclerosis. This results in a reduction in disease activity and slowing of disease progression.
Approved indications
- Relapsing multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Infusion-related reactions
- Herpes simplex virus reactivation
- Upper respiratory tract infections
- Headache
- Nausea
Key clinical trials
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (PHASE3)
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocrevus-US CI brief — competitive landscape report
- Ocrevus-US updates RSS · CI watch RSS
- Sandoz portfolio CI